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Introduction: There is scarce information regarding clinical evolution of HBV infection in
renal  transplant patients.
Aims:  To evaluate the prevalence of acute exacerbation in HBV-infected renal transplant
patients  and its association with the time after transplantation, presence of viral replication,
clinical  evolution, and use of antiviral prophylaxis.
Materials and methods: HBV infected renal transplant patients who underwent regular follow-
up  visits at 6-month intervals were included in the study. The criteria adopted to characterize
exacerbation  were: ALT >5× ULN and/or >3× baseline level. Predictive factors of exacerba-
tion  evaluated were age, gender, time on dialysis, type of donor, post-transplant time, ALT,
HBeAg, HBV-DNA, HCV-RNA, immunosuppressive therapy, and use of antiviral prophylaxis.
Results:  140 HBV-infected renal transplant patients were included (71% males; age 46 ± 10
years; post-renal transplant time 8 ± 5 years). During follow-up, 25% (35/140) of the patients
presented exacerbation within 3.4 ± 3 years after renal transplant. Viral replication was
observed  in all patients with exacerbation. Clinical and/or laboratory signs of hepatic insuf-
ﬁciency were present in 17% (6/35) of the patients. Three patients died as a consequence of
liver failure. In univariate analysis variables associated with exacerbation were less frequent
use  of prophylactic/preemptive lamivudine and of mycophenolate mofetil. Lamivudine use
was the only variable independently associated with exacerbation, with a protective effect.
Conclusions:  Acute exacerbation was a frequent and severe event in HBV-infected renal trans-ylactplant  patients. Prophall HBsAg-positive renal t
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Introduction
According to the World Health Organization, the number of
chronic  hepatitis B virus (HBV) carriers exceeds 350 million
worldwide.1 Among renal transplant patients HBV infection
continues to be an important cause of morbidity and mortal-
ity,  although its incidence declined after the introduction of
hepatitis  B vaccine in 1982 and as a result of improved overall
care  during hemodialysis.2 The prevalence of chronic hepatitis
B  after kidney transplantation ranges from 2 to 21% according
to  geographic regions.3
Although data about the natural course of HBV infection
in  renal transplant recipients are scarce, evidence indicates
that  viral replication is accelerated by immunosuppression
and that HBV-related liver disease is more  aggressive in renal
transplant  recipients.4 Some studies have demonstrated that
the  progression of liver disease could occur in more  than 80%
of  HBsAg-positive renal transplant patients, with a high mor-
tality  rate5 and higher incidence of graft loss.6
Reactivation of HBV infection in immunosuppressed
patients can be separated into three phases: (1) increase in
HBV  replication; (2) appearance of hepatic injury (ALT ﬂares)
and  (3) recovery.7 Biochemical evidence of reactivation is char-
acterized  by ALT ﬂares and sometimes associated loss of liver
function  from ranging 30–70% in different case series.8 More
recently,  Murakami et al.9 reported reactivation in 45% (5/11)
of  renal transplant patients with hepatitis B surface antigen
positive  and Savas et al.10 observed reactivation in 70% (14/20)
within  a mean period of 16.3 ± 7.1 months after transplanta-
tion.
In  view of the severity of reports, prophylaxis with
lamivudine, a nucleoside analog, has become common
practice to prevent reactivation of HBV infection after
renal  transplantation.11 However, prolonged administration
of  lamivudine may  result in the development of treatment
resistance.12 The rate of emergence of resistance mutations
progressively increases with duration of therapy, exceeding
30%  within two years in immunocompetent patients.13 Unfor-
tunately,  resistance is accelerated after transplantation and its
occurrence is higher in renal transplant patients (30–57% after
1–2  years), reﬂecting steroid-enhanced HBV replication.14
In view of the high prevalence of HBV infection in this spe-
cial  group of patients and the scarce data regarding the natural
history  of infection, a better understanding of the evolution
of  HBV in renal transplant recipients is necessary to estab-
lish  the best management strategy for these patients and the
indication  of antiviral treatment in this population.
The objectives of the present study were  to evaluate the
prevalence of biochemical exacerbation in renal transplant
patients chronically infected with HBV and to evaluate the
factors  related to its occurrence.
Materials  and  methods
PatientsRenal transplant patients followed-up at a post-transplant
outpatient clinic in the Federal University of Sao Paulo, Brazil,
who  were  persistently HBsAg positive for more than 6 months, 1 4;1  8(6):625–630
were  referred to liver evaluation at the Hepatitis outpatient
clinic  of the same institution. The patients who  underwent
regular follow-up visits at 6-month intervals were  included in
the study. Patients consuming more  than 50 g of alcohol per
day  and HIV-infected patients were excluded.
Method
Variables  analyzed
All patients were evaluated regarding age, gender, time on
dialysis,  type of donor (cadaveric vs living donor), time of post-
transplant  follow-up, alanine aminotransferase (ALT) index,
HBeAg,  quantitative HBV-DNA (determined by real-time PCR),
anti-HCV,  HCV-RNA (determined by real-time PCR), immuno-
suppressive therapy, and use or not of lamivudine, after
reviewing the data from medical charts. Histological variables
were  also analyzed in patients submitted to a liver biopsy
after  kidney transplantation. A liver biopsy was  indicated in
patients with evidence of viral replication, irrespective of ALT
levels.  The patients were  divided into two groups according to
the stage of hepatic ﬁbrosis using the METAVIR scoring system
(F0–F2  vs. F3–F4).15
Biochemical  and  serological  tests
For biochemical analysis, serum ALT was  reported as the quo-
tient  between the mean value obtained and the upper limit of
normal  (ULT) for gender.
HBeAg  was determined using the HBeAg IMx  assay (Abbott
Laboratories, Chicago, IL, USA). Anti-HCV reactivity was deter-
mined  by the IMx HCV assay, version 3.0 (Abbott Laboratories).
Molecular  tests
Hepatitis C  virus-RNA.  HCV-RNA was determined in all anti-
HCV  positive samples by qualitative PCR using Amplicor kits
(Roche  Diagnostics, Basel, Switzerland). The lower detection
limit  of the method was 50 IU/mL.
Hepatitis  B  virus-DNA.  Quantitative real-time PCR assays
were  performed using the ABI PRISM 7700 sequence detection
system  (Applied Biosystems). HBV-DNA was  inconsistently
detected in dilutions containing less than 50 IU/ML, which was
the  3 SD limit of detection (99.9% conﬁdence interval).
Histological  analysis
A liver biopsy was  indicated in all patients showing evidence
of  HBV replication. All biopsy slides were  reviewed by a single
pathologist. The stage of ﬁbrosis was  analyzed semiquantita-
tively based on the METAVIR classiﬁcation (F0–F4).15
Biochemical  exacerbation
Renal transplant patients under follow-up were  evaluated
regarding the occurrence of biochemical exacerbation. The
following  criteria were adopted for the characterization of bio-
chemical exacerbation: ALT >5 times the upper limit of normal
and/or  >3 times the baseline level.16 In order to identify predic-
tive  factors of exacerbation the following variables and those
cited  above were evaluated in patients with and without bio-
chemical  exacerbation: interval between transplantation and
the  occurrence of exacerbation, presence of ascites, jaundice
or  encephalopathy, maximum ALT level, serum bilirubin and
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Table 1 – General characteristics of the HBsAg-positive
renal transplant patients (n = 140).
Male gender (%) 99 (71)
Age (years), mean ± SD 46 ± 10
Time  on dialysis (years) 5.2 ± 3.8
Cadaveric donor (%) 68 (49)
Post-transplant time (years), mean ± SD 8 ± 5
HCV-RNA positive (%) 28 (20)
HBeAg positive (%) 70 (50)
HBV-DNA (log)a, mean ± SD 6.64 ± 2.09
HBV-DNA (%)a
<200 IU/mL 10 (9.5)
200–2000 IU/mL 8  (7.6)
≥2000 IU/mL 87 (83)
Fibrosis (F3–4) (%)b 21 (23.1)
Triple immunosuppression (%) 107 (76%)
Immunosuppression (%)
Regimen  including MMF 42/140 (32)
Regimen including AZA 89/140 (63.6)
Regimen including CSA 87/140 (62)
MMF, mycophenolate mofetil; AZA, azathioprine; CSA, cyclosporine
A.
a n = 105.
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In the present study, biochemical exacerbation was a fre-b n = 95.
lbumin levels, prothrombin activity, serological or molecular
arkers  of viral replication, and outcome (spontaneous cure,
reatment  response with lamivudine, or death). The presence
f  clinical signs such as ascites, encephalopathy or a reduction
n  serum albumin levels (<3 g/dL) and prothrombin activity
<70%)  was  deﬁned as signs of hepatic insufﬁciency.
A liver biopsy was  obtained at exacerbation, when possible,
or  staging ﬁbrosis, grade of necroinﬂammatory activity, and
etection  of HBcAg in tissue.15
The study was  carried out in accordance with the Helsinki
eclaration. All patients selected for the study gave written
nformed  consent. The study protocol was  approved by the
ocal  Ethical Committee (number 2143/08).
tatistical  analysis
he Chi-square test was  used for comparing categorical vari-
bles  and the Student t-test and Mann–Whitney test for
umerical variables. Binary logistic regression analysis was
erformed  to identify the variables independently associated
o  biochemical exacerbation. A level of signiﬁcance of 0.05
˛  = 5%) was  adopted.
esults
 total of 140 HBsAg-positive renal transplant patients were
ollowed  up at the Hepatitis outpatient clinic of Federal Univer-
ity  of Sao Paulo. Ninety-nine (71%) were  male, the mean age
as  46 ± 10 years (range: 17–74). The patients were included
n  different time points after renal transplant with a mean
ime  of post-transplant follow-up of 8 ± 5 years. The general
haracteristics of the patients are shown in Table 1.
During  follow-up, 25% (35/140) of the patients presented
levated ALT, characterizing biochemical exacerbation. This4;1 8(6):625–630  627
event was  observed within a mean period of 3.4 ± 3 years after
kidney  transplantation (median of two years).
Among the patients presenting exacerbation, viral repli-
cation  (HBV-DNA and/or HBeAg and/or HBcAg in tissue) was
observed  in all patients in whom this variable could be ana-
lyzed  (n = 33). Viral load was  determined in 20/35 patients by
real-time  PCR and the median was 29 × 106 IU/mL in these
patients.
A  liver biopsy was  obtained from 83% (29/35) of the patients
with  biochemical exacerbation. With respect to ﬁbrosis, 76%
(22/29)  of the patients had ﬁbrosis stage 0–2 and 24% (7/29) had
stage  3–4. Mild necroinﬂammatory activity was  observed in
27.5%  (8/29) of the patients, moderate activity in 65.5% (19/29),
and  intense activity in 7% (2/29).
Clinical and/or laboratory signs of hepatic insufﬁciency
were observed in 17% (6/35) of the patients, encephalopathy
in 17% (6/35), ascites in 11.4% (4/35), and signiﬁcant laboratory
abnormalities in 14% (5/35). Three of these patients died as a
consequence  of liver failure despite the use of lamivudine in
two of these cases.
Among  the 35 patients with exacerbation, 10/35 were  not
treated  with lamivudine. Spontaneous resolution of the bio-
chemical  abnormalities without loss of liver function was
observed  in 9/10 not treated patients and one patient died with
liver  failure. According to lamivudine use, in only 9% (3/35)
of  the patients the drug was  used as preemptive/prophylactic
therapy. Treatment with lamivudine after onset of exacerba-
tion  was  administered to 22/35 patients, with clinical response
in  18/22. The mean time to ALT normalization was 8.8 months
in  these patients. When lamivudine was  given at the time of
exacerbation,  no difference in mortality due to hepatic insuf-
ﬁciency  was  observed between treated and untreated patients
(9%  vs. 10%; p = 0.69).
Table 2 lists the clinical and laboratory characteristics
associated with biochemical exacerbation. Variables asso-
ciated  with the occurrence of biochemical exacerbation
were a less frequent use of mycophenolate mofetil in the
immunosuppression regimen and a lower proportion of pro-
phylactic/preemptive administration of lamivudine.
In the logistic regression model only pre-exacerbation
lamivudine use was found to be independently associated
with biochemical exacerbation (Table 3) showing a protective
effect.
Discussion
Chronic HBV infection presents an unfavorable course in
immunosuppressed patients. Faster progression to hepatic
ﬁbrosis  and a higher frequency of complications of liver dis-
ease  have been demonstrated in renal transplant recipients.8
Additionally, cases of reactivation of HBV infection after renal
transplantation have been reported, sometimes presenting a
fulminant course.17 However, data regarding the frequency
and  severity of episodes of biochemical exacerbation in renal
transplant  patients infected with HBV are scarce.quent  event in renal transplant patients chronically infected
with  HBV and was  observed in 25% of the patients studied
over  a follow-up period of 8 ± 5 years. In immunocompetent
628  b r a z j i n f e c t d i s . 2 0 1 4;1  8(6):625–630
Table 2 – Comparison between patients with and without biochemical exacerbation.
Without exacerbation (n = 105) With exacerbation (n = 35) p-value
Male gender (%) 70% 71% 0.92
Age (years), mean ± SD 45 ± 10 46 ± 10 0.64
Time on dialysis (years) 5.4 ± 3.9 4.5 ± 3.2 0.26
Post-transplant time (years) 7.3 ± 5.0 8.9 ± 4.2 0.10
Cadaver donor (%) 51% 44% 0.49
Previous RTx 13% 14% 0.99
Pre-exacerbation ALT (×ULN, median) 0.54 0.68 0.41
HCV-RNA positive (%) 23% 11% 0.14
HBeAg positive (%) 52% 46% 0.51
Pre-exacerbation log HBV-DNA (median) 7.68 4.53 0.09
Fibrosis stage 3–4 23% 24% 0.87
Triple immunosuppression 80% 66% 0.09
Immunosuppression with MMF 34% 17% 0.05
Immunosuppression with AZA 63% 66% 0.76
Immunosuppression with CSA 62% 69% 0.36
Pre-exacerbation lamivudine (n = 41) 36.2% 9% 0.002
RTx, 
Bold values indicates level of signiﬁcance of 0.05 was adopted.
MMF, mycophenolate mofetil; AZA, azathioprine; CSA, cyclosporine; 
patients, biochemical exacerbation is frequent and generally
related  to HBeAg seroconversion.16 Yuen et al. followed up a
cohort  of 3063 patients and observed biochemical exacerba-
tion  in 35% of patients over a mean follow-up period of 29
months.18 In renal transplant patients exacerbation is related
to  a distinct phenomenon and has a marked negative impact
because  of the greater severity of these episodes in this speciﬁc
group  of patients.19
In view of the immunosuppression to which they are sub-
mitted,  renal transplant patients generally present intense
viremia,20 with very high levels of HBV-DNA even in HBeAg-
negative patients.21 Matos et al.4 demonstrated a viral load
higher  than 2.000 IU/mL in 80% of HBeAg-negative transplant
patients with chronic hepatitis B. Most of these cases proba-
bly  correspond to mutations in the pre-core or core promoter
region  of HBV since no HBeAg was  detected and viral replica-
tion  was  clinically signiﬁcant.
The  occurrence of biochemical exacerbation of HBV infec-
tion  in renal transplant patients is more  related to the immune
reconstitution observed after reduction of immunosuppres-
sion. Patients receive more  intense immunosuppression
during the immediate post-transplant period, which promotes
a  signiﬁcant increase in viral load associated with a pattern
of  immunotolerance to HBV. The progressive reduction in the
dose  of the immunosuppressive agents over time leads to
improvement in the immune status and consequent greater
hepatocellular damage due to the loss of immunotolerance
to the virus.7 In addition, exacerbation might be mediated by
other  mechanisms, such as hepatotoxicity of the immunosup-
pressive drugs. In this respect, azathioprine and cyclosporine
have  been shown to cause liver injury accompanied by a sig-
niﬁcant  increase in aminotransferases.22
Table 3 – Logistic regression (ﬁnal model).
p-value 
Pre-exacerbation lamivudine use 0.005 renal transplantation; ULN, upper limit of normal.
In the present study, viral reactivation was observed within
an  average 3.4 ± 3 years (median of 2 years) after renal trans-
plantation, in contrast to other studies in which this event
usually  occurred within the ﬁrst post-transplant year.9–11,20
This ﬁnding suggests that exacerbation may  not be such an
early  event, and may  be possibly related to modiﬁcations of the
immunosuppressive regimen as time goes by. This should be
considered in the recommendations regarding the duration of
prophylactic  antiviral treatment, which should be prolonged
during  the post-transplant period and should not be restricted
to  the ﬁrst 12 or 24 months post-transplant.
In addition to its high frequency, biochemical exacerba-
tion was  a serious event and was  associated with clinical and
laboratory  signs of hepatic insufﬁciency in 17% (6/35) of the
cases.  Three of these patients died as a consequence of hepatic
failure.  Another study involving the same type of patients
also  reported a high rate of liver dysfunction (30%) associated
with  reactivation of HBV infection.11 In the present study it
was  not possible to identify the factors related to the sever-
ity  of reactivation, due to the small number of patients with
hepatic  failure. Thus, all HBsAg-positive kidney transplant
patients should be carefully monitored. Biochemical exacer-
bation  needs to be rapidly recognized and control measures
should be readily adopted in view of the high morbidity and
mortality  related to this event.
In view of the high frequency and severity of the bio-
chemical exacerbation that occur in renal transplant patients
infected  with HBV, it would be important to determine the
associated  factors in order to allow for early identiﬁcation of
patients  at risk of this event. No demographic, epidemiological
or  laboratory variables could predict the occurrence biochemi-
cal  exacerbation. In the univariate analysis, the only variables
OR 95% CI
0.17 0.05–0.58
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hat were associated with this event were  the inclusion of
ycophenolate mofetil in the immunosuppression regimen,
hich  was  less frequent among patients with exacerbation,
nd  preemptive or prophylactic administration of lamivudine,
hich  was  also less frequent among patients with exacerba-
ion.
One  possible explanation for the less frequent use of
ycophenolate mofetil in the immunosuppression regimen
mong  patients with exacerbation might have been the potent
mmunosuppressive effect of this drug on the host immune
esponse, which would eventually reduce immunomediated
epatocellular damage by more  efﬁciently preventing immune
econstitution over time. Another possibility is related to the
ntiviral  effect of mycophenolate mofetil in inhibiting HBV
eplication,  which has been demonstrated in vitro.23
However, the most important observation in this study was
hat  lamivudine was  effective in the prevention of exacerba-
ion  as demonstrated by the signiﬁcantly higher proportion
f  patients using this drug in the group without exacerbation
hen compared to the group with exacerbation (36% vs. 9%;
 = 0.002). This was  the only variable independently associated
ith  exacerbation in this study, supporting the recommen-
ation of preemptive/prophylactic administration of antiviral
rophylaxis to all patients with chronic HBV infection receiv-
ng  a renal transplant.
On  the other hand, when lamivudine was initiated at the
ime  of exacerbation, no difference in mortality due to hepatic
nsufﬁciency was  observed between treated and untreated
atients. In the study of Han et al.,11 although lamivudine pro-
oted  normalization of ALT levels and suppression of viral
eplication  in all treated cases, it did not prevent the progres-
ion  of histological injury. These data suggest that lamivudine
as  poor efﬁcacy as a rescue drug in cases of exacerbation and
hat  treatment should preferentially and ideally be initiated
efore  transplantation since immunosuppression has not yet
een instituted and the patient therefore presents lower viral
oads.  Nevertheless, administration of antiviral drugs as early
s  possible should be considered even for patients who have
ot  received pre-transplant prophylactic/preemptive therapy.
Finally,  so far there are no studies evaluating more  potent
ntiviral  drugs with a higher genetic barrier to resistance in
his  particular subgroup of patients. However, this new gener-
tion  of drugs will probably become the ideal option to prevent
xacerbation of HBV infection in renal transplant patients.
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